Integra LifeSciences to Present at the Piper Jaffray Health Care and JP Morgan SMid Cap Conferences in December

Integra LifeSciences to Present at the Piper Jaffray Health Care and JP Morgan SMid Cap Conferences in December 14.2 KB

PLAINSBORO, N.J., Nov. 20, 2009 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it will present at two conferences in December.

Stuart Essig, President and Chief Executive Officer of Integra, will present at both conferences in New York City as follows:



  Tuesday, December 1st, 2009 at 12:00 noon, at the Piper Jaffray
  21st Annual Health Care Conference at the New York Palace;

  and Thursday, December 3rd, 2009 at 12:45 PM, at the J.P. Morgan
  2009 SMid Cap Conference at 383 Madison Avenue.

There will be no webcast available for the above conferences.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is a global medical device company dedicated to improving the quality of life for millions of patients every year. Our products are used primarily in orthopedics, neurosurgery and general surgery. Headquartered in Plainsboro, New Jersey, Integra has research and manufacturing facilities throughout the world. For more information, visit www.Integra-LS.com.

Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2008 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

IART-G

CONTACT:  Integra LifeSciences Holdings Corporation
          John B. Henneman, III, Executive Vice President Finance 
          and Administration and Chief Financial Officer
            (609) 275-0500
            jhenneman@Integra-LS.com
          Investor Relations:
          Angela Steinway
            (609) 936-2268
            angela.steinway@Integra-LS.com